Please provide your email address to receive an email when new articles are posted on . Atezolizumab monotherapy induced objective responses in more than one-third of patients. No treatment-related ...

A clinical trial has resulted in the first approval of a treatment for advanced alveolar soft part sarcoma (ASPS). The immunotherapy drug atezolizumab (Tecentriq) was recently approved by the U.S.

Credit: Thinkstock. The approval was based on data from a phase 2 study that included 49 patients with unresectable or metastatic ASPS. The Food and Drug Administration (FDA) has approved Tecentriq ...

Alveolar soft part sarcoma (ASPS) remains one of the rare and enigmatic soft tissue malignancies, principally affecting adolescents and young adults. Despite its low incidence, recent research has ...

Tecentriq was approved by the FDA for adults and children aged two years and older with advanced alveolar soft part sarcoma, a disease typically diagnosed in approximately 80 patients per year in the ...

A clinical trial led by the National Cancer Institute (NCI), part of the National Institutes of Health, has resulted in the first approval of a treatment for advanced alveolar soft part sarcoma (ASPS) ...

The positions in the table below reflect the Cure Alveolar Soft Part Sarcoma International's position overall, domestically, within their sector, and in various subject areas based on their Share.

Safety and efficacy of letetresgene autoleucel (lete-cel; GSK3377794) in advanced myxoid/round cell liposarcoma (MRCLS) following high lymphodepletion (Cohort 2): Interim analysis. This is an ASCO ...

Farhad Zamani, MD, Assistant Professor of Gastroenterology, GI and Liver Disease Research Center, Iran University of Medical Sciences, Tehran, Iran Mosadegh Jabbari, MD, Assisstant Professor of ...

Please provide your email address to receive an email when new articles are posted on . The FDA approved atezolizumab for adults and children aged 2 years or older with unresectable or metastatic ...